GB2601667A - Combination therapy to achieve enhanced antimicrobial activity - Google Patents

Combination therapy to achieve enhanced antimicrobial activity Download PDF

Info

Publication number
GB2601667A
GB2601667A GB2202352.7A GB202202352A GB2601667A GB 2601667 A GB2601667 A GB 2601667A GB 202202352 A GB202202352 A GB 202202352A GB 2601667 A GB2601667 A GB 2601667A
Authority
GB
United Kingdom
Prior art keywords
group
corresponds
polycarbonate polymer
antimicrobial activity
antirheumatic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB2202352.7A
Other versions
GB2601667B (en
GB202202352D0 (en
Inventor
Hedrick James
Yan Yang Yi
Ding Xin
Yang Chuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
International Business Machines Corp
Original Assignee
Agency for Science Technology and Research Singapore
International Business Machines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/531,493 external-priority patent/US11007216B2/en
Priority claimed from US16/531,432 external-priority patent/US11028264B2/en
Application filed by Agency for Science Technology and Research Singapore, International Business Machines Corp filed Critical Agency for Science Technology and Research Singapore
Publication of GB202202352D0 publication Critical patent/GB202202352D0/en
Publication of GB2601667A publication Critical patent/GB2601667A/en
Application granted granted Critical
Publication of GB2601667B publication Critical patent/GB2601667B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/02—Aliphatic polycarbonates
    • C08G64/0208—Aliphatic polycarbonates saturated
    • C08G64/0225—Aliphatic polycarbonates saturated containing atoms other than carbon, hydrogen or oxygen
    • C08G64/0241—Aliphatic polycarbonates saturated containing atoms other than carbon, hydrogen or oxygen containing nitrogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Techniques regarding enhancing antimicrobial activity of antirheumatic agents by combination therapy are provided. For example, one or more embodiments described herein can regard a chemical composition comprising a polycarbonate polymer functionalized with a guanidinium functional group. The chemical composition can also comprise an antirheumatic agent, and the polycarbonate polymer can enhance an antimicrobial activity of the antirheumatic agent.

Claims (20)

1. A chemical composition comprising: a polycarbonate polymer functionalized with a guanidinium functional group; and an antirheumatic agent, wherein the polycarbonate polymer enhances an antimicrobial activity of the antirheumatic agent.
2. The chemical composition of claim 1, wherein the antirheumatic agent is (2,3,4,6-Tetra-Gâ ace1yM-thio-pâ D-giucopyranosaio-KS1)(triethylphosphoranylidene)goid.
3. The chemical composition of claim 2, wherein the antimicrobial activity inhibits a Gram-negative bacterium.
4. The chemical composition of claim 2, wherein the polycarbonate polymer enhances the antimicrobial activity by translocating across a cell membrane and interacting with a cytosolic member of a target microbe.
5. The chemical composition of claim 4, wherein the cytosolic member is selected from a group consisting of a protein, an enzyme, and a gene.
6. The chemical composition of claim 4, wherein the antimicrobial activity comprises enhancing reactive oxygen species generation within the target microbe by the antirheumatic agent.
7. The chemical composition of claim 2, wherein the polycarbonate polymer has a structure characterized by a chemical formula: wherein "R1â corresponds to a first functional group selected from a first group consisting of: a biotin group, a sugar group, a first alkyl group, and a first aryl group; wherein "R2â corresponds to a second functional group selected from a second group consisting of a hydrogen, a second alkyl group, and a second aryl group; wherein "Xâ corresponds to a spacer structure selected from a third group consisting of a third alkyl group and a third aryl group; and wherein "nâ corresponds to an integer greater than or equal to 1 and less than or equal to one thousand.
8. A method comprising: enhancing an antimicrobial activity of an antirheumatic agent by a combination therapy, wherein the combination therapy comprises the antirheumatic agent and a polycarbonate polymer functionalized with a guanidinium functional group.
9. The method of claim 8, wherein the antirheumatic agent is (2,3!4!6-Teira-0-acety1-1~thio~p-D- giucopyranosato~KS1){ir!eihylphosphoranyydene)gold.
10. The method of claim 9, wherein the enhancing the antimicrobial activity of the antirheumatic agent comprises translocating the polycarbonate polymer across a cell membrane and interacting the polycarbonate polymer with a cytosolic member of a microbe targeted by the antimicrobial activity, wherein the cytosolic member is selected from a group consisting of a protein, an enzyme, and a gene.
11. The method of claim 10, wherein the antimicrobial activity comprises increasing reactive oxygen species generation within the microbe by the antirheumatic agent.
12. The method of claim 9, wherein the antimicrobial activity inhibits a Gram-negative bacterium.
13. The method of claim 8, wherein the combination therapy mitigates an onset of resistance towards the antimicrobial activity by a microbe targeted by the antirheumatic agent.
14. The method of claim 9, wherein the polycarbonate polymer has a structure characterized by a chemical formula: wherein "R1â corresponds to a first functional group selected from a first group consisting of: a biotin group, a sugar group, a first alkyl group, and a first aryl group; wherein "R2â corresponds to a second functional group selected from a second group consisting of a hydrogen, a second alkyl group, and a second aryl group; wherein "Xâ corresponds to a spacer structure selected from a third group consisting of a third alkyl group and a third aryl group; and wherein "nâ corresponds to an integer greater than or equal to 1 and less than or equal to one thousand.
15. A method comprising: treating a bacteria infection via a combination therapy that comprises an antirheumatic agent and a polycarbonate polymer functionalized with a guanidinium functional group, wherein the polycarbonate polymer enhances an antibacterial activity of the antirheumatic agent.
16. The method of claim 15, wherein the antirheumatic agent is (2!3!4,6-Tetra-0-acetyl-1-thio-p-D- giucopyranosato~KS1){ir!eihylphosphoranyydene)gold.
17. The method of claim 16, further comprising: translocating the polycarbonate polymer across a cell membrane of a bacterium of the bacteria infection; and precipitating a cytosolic member of the bacterium via an interaction between the cytosolic member and the polycarbonate polymer, wherein the cytosolic member is selected from a group consisting of a protein, an enzyme, and a gene.
18. The method of claim 17, further comprising: increasing reactive oxygen species generation within the bacterium via the antirheumatic agent.
19. The method of claim 18, wherein the bacterium is a Gram-negative bacterium.
20. The method of claim 19, wherein the polycarbonate polymer has a structure characterized by a chemical formula: wherein "R1â corresponds to a first functional group selected from a first group consisting of: a biotin group, a sugar group, a first alkyl group, and a first aryl group; wherein "R2â corresponds to a second functional group selected from a second group consisting of a hydrogen, a second alkyl group, and a second aryl group; wherein "Xâ corresponds to a spacer structure selected from a third group consisting of a third alkyl group and a third aryl group; and wherein "nâ corresponds to an integer greater than or equal to 1 and less than or equal to one thousand.
GB2202352.7A 2019-08-05 2020-07-15 Combination therapy to achieve enhanced antimicrobial activity Active GB2601667B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/531,493 US11007216B2 (en) 2019-08-05 2019-08-05 Combination therapy to achieve enhanced antimicrobial activity
US16/531,432 US11028264B2 (en) 2019-08-05 2019-08-05 Polylysine polymers with antimicrobial and/or anticancer activity
PCT/IB2020/056644 WO2021024054A1 (en) 2019-08-05 2020-07-15 Combination therapy to achieve enhanced antimicrobial activity

Publications (3)

Publication Number Publication Date
GB202202352D0 GB202202352D0 (en) 2022-04-06
GB2601667A true GB2601667A (en) 2022-06-08
GB2601667B GB2601667B (en) 2023-01-25

Family

ID=74503332

Family Applications (2)

Application Number Title Priority Date Filing Date
GB2202615.7A Active GB2601680B (en) 2019-08-05 2020-07-15 Polylysine polymers with antimicrobial and/or anticancer activity
GB2202352.7A Active GB2601667B (en) 2019-08-05 2020-07-15 Combination therapy to achieve enhanced antimicrobial activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB2202615.7A Active GB2601680B (en) 2019-08-05 2020-07-15 Polylysine polymers with antimicrobial and/or anticancer activity

Country Status (5)

Country Link
JP (2) JP2022543409A (en)
CN (2) CN114245740A (en)
DE (2) DE112020002996T5 (en)
GB (2) GB2601680B (en)
WO (2) WO2021024054A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117980377A (en) * 2021-07-23 2024-05-03 新加坡科技研究局 Functionalized polypeptides, nanoparticles and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007098A2 (en) * 2003-07-08 2005-01-27 New York University Nucleic acid therapy to enhance cartilage repair
US20150038671A1 (en) * 2013-05-30 2015-02-05 Keykavous Parang Efficient Synthesis of CN2097 and RC7 and Their Analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100120246A (en) * 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 Anti-il-6 antibodies, compositions, methods and uses
FR2851465B1 (en) * 2003-02-25 2005-04-08 Oreal USE OF POLYLYSINS TO FORM REMANENT DEPOSITION ON KERATINIC MATERIALS
US20130158077A1 (en) * 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9854806B2 (en) * 2015-05-19 2018-01-02 International Business Machines Corporation Antimicrobial guanidinium and thiouronium functionalized polymers
EA201891142A1 (en) * 2015-11-10 2018-11-30 Элизабет Маккенна CONTROL OF CELL OXIDATIVE REDUCING LEVELS
US11191777B2 (en) * 2018-06-20 2021-12-07 International Business Machines Corporation Antimicrobial guanidinium macromolecules with bacteria targeting moieties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007098A2 (en) * 2003-07-08 2005-01-27 New York University Nucleic acid therapy to enhance cartilage repair
US20150038671A1 (en) * 2013-05-30 2015-02-05 Keykavous Parang Efficient Synthesis of CN2097 and RC7 and Their Analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIN, Willy, et al., "A macromolecular approach to eradicate multidrug resistant bacterial infections while mitigating drug resistance onset, " Nature Communications, vol. 9, 02 March 2018 (2018-03-02), pages 1 - 14 *
Dangol, Manita, et al., "Innovative polymeric system (IPS) for solvent-free lipophilic drug transdermal delivery via dissolving microneedles," Journal of Controlled Release, vol. 223, 28 December2015 (2015-12-28), pages 118-125 *
Pearson, Samuel, et al., "Glycopolymer Self-Assemblies with Gold(I) Complexed to the Core as a Delivery System for Auranofin", Macromolecules, vol. 48, 23 January 2015 (2015-01-23), pages 1065-1076 *
Song, Xia, et al., "B-methasone-containing biodegradable poly(lactide-coglycolide) acid microspheres for intraarticular injection: effect of formulation parameters on characteristics and in vitro release," Pharmaceutical Development and Technology, Vol.18, No. 5, 31 December 2013 (2013-12-31), pages *

Also Published As

Publication number Publication date
JP2022543408A (en) 2022-10-12
GB2601667B (en) 2023-01-25
JP2022543409A (en) 2022-10-12
DE112020002996T5 (en) 2022-05-19
GB2601680A (en) 2022-06-08
WO2021024054A1 (en) 2021-02-11
WO2021024057A1 (en) 2021-02-11
CN114174276A (en) 2022-03-11
GB2601680B (en) 2023-02-22
DE112020002988T5 (en) 2022-05-19
CN114245740A (en) 2022-03-25
GB202202352D0 (en) 2022-04-06
JP7481077B2 (en) 2024-05-10
GB202202615D0 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
Evans et al. Susceptibility of bacterial biofilms to tobramycin: role of specific growth rate and phase in the division cycle
Čáp et al. Reactive oxygen species in the signaling and adaptation of multicellular microbial communities
Akiyama et al. Effects of zinc oxide on the attachment of Staphylococcus aureus strains
Pankievicz et al. RNA-seq transcriptional profiling of Herbaspirillum seropedicae colonizing wheat (Triticum aestivum) roots
Biswas et al. Molecular mechanisms of Staphylococcus and Pseudomonas interactions in cystic fibrosis
CN109714969B (en) Biological insecticide for potato late blight
US11058716B2 (en) Method, target and application for NO accumulation to decrease Pseudomonas aeruginosa invasiveness
Weiland-Bräuer et al. Metagenomic quorum quenching enzymes affect biofilm formation of Candida albicans and Staphylococcus epidermidis
Cotton et al. The role of alginate in P. aeruginosa PAO1 biofilm structural resistance to gentamicin and ciprofloxacin
GB2601667A (en) Combination therapy to achieve enhanced antimicrobial activity
Gao et al. Endophytic Streptomyces hygroscopicus OsiSh-2-mediated balancing between growth and disease resistance in host rice
Yu et al. Soil amoebae affect iron and chromium reduction through preferential predation between two metal-reducing bacteria
de Vries et al. Evolutionary genomic insights into cyanobacterial symbioses in plants
Syal et al. Synthetic glycolipids and (p) ppGpp analogs: development of inhibitors for mycobacterial growth, biofilm and stringent response
Charyulu et al. Antimicrobial activity of secondary metabolite from marine isolate, Pseudomonas sp. against Gram positive and negative bacteria including MRSA
Dhouib et al. Maturation of molybdoenzymes and its influence on the pathogenesis of non-typeable Haemophilus influenzae
Salman et al. Interaction of fluorescent pseudomonads with Pythium ultimum and Rhizoctonia solani in cucumber roots.
Grahl et al. The Yin and Yang of phenazine physiology
CN115595279A (en) Helicobacter pylori solid culture medium
Aziz Antibiotic Activity of Endophytic Bacteria isolated from Euchema cottoni of North Galesong Sea, Takalar
Kyd et al. Interactions and mechanisms of respiratory tract biofilms involving Streptococcus pneumoniae and nontypeable Haemophilus influenzae
RU2279079C2 (en) Method for detecting protective activity microorganisms in fenton effect cases
Sabra et al. Food web and metabolic interactions of the lung inhabitants Streptococcus pneumoniae and Pseudomonas aeruginosa
Wurzer The interaction of Streptomyces-like bacteria and model microorganisms in secondary metabolite production, motility and hemolytic activities-Experimental
Cuffini et al. The erythromycin-resistance in S. pyogenes does not limit the human polymorphonuclear cell antimicrobial activity